The Effect of Fluoxetine on Progression in Progressive Multiple Sclerosis: A Double-Blind, Randomized, Placebo-Controlled Trial

Table 3

Cox regression analyses of time to progression by treatment group controlled for gender, disease course, age and disease duration.

		Reference	HR (95% CI)	𝑃 value
Treatment	Placebo	1.00
	Fluoxetine		1.15 (0.38–3.43)	0.81
Gender	Male	1.00
	Female		2.96 (0.96–9.10)	0.06
Disease course	PPMS	1.00
	SPMS		1.08 (0.25–4.64)	0.92
Age	Per year increase		1.05 (0.96–1.15)	0.26
Disease duration	Per year increase		1.00 (0.92–1.08)	0.94